Adce-B05
Solid Tumors (Phase 1)
Adcendo ApSPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the Solid Tumors (Phase 1) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
USL-311 Proximagen, LLC | Phase 1/2 | CC |
Lomustine Proximagen, LLC | Phase 1/2 | CC |
Arog4-01 Aromics Therapeutics | Phase 1 | CC |
hsk42360 Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | CC |
Rndo-564 Rondo Therapeutics | Phase 1 | CC |
View all 10 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →